Ciforadenant is under clinical development by Corvus Pharmaceuticals and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData, Phase I drugs for Relapsed Multiple Myeloma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ciforadenant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ciforadenant overview

Ciforadenant is under development for the treatment of solid tumors such as non-small cell lung cancer, malignant melanoma, renal cell carcinoma, triple negative breast cancer, and metastatic castration-resistant prostate cancer, head and neck cancer, colorectal cancer with microsatellite instability (MSI),n oropharyngeal cancers associated with HPV infection, bladder cancer,cervical cancer, uterine cancer, sarcoma, relapsed or refractory multiple myeloma, endometrial cancer (as a second and third line therapy) and metastatic renal cell carcinoma. It is administered through oral route in the form of capsule. The drug candidate is a small molecule which acts by targeting A2A receptor. It was also under development for the treatment of attention deficit hyperactivity disorder (ADHD) and Parkinson's disease. It is a backup drug of BIIB014 (vipadenant).

Corvus Pharmaceuticals overview

Corvus Pharmaceuticals (Corvus Pharma) is a clinical-stage biopharmaceutical company. It is engaged in the development and commercialization of immuno-oncology therapies that are used for treating cancer. Corvus Pharma’s product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in phase I clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine produced by the tumor cells. Corvus Pharma’s product pipeline also includes adenosine A2B receptor antagonist, ITK inhibitor and myeloid cell suppression. The company operates in the US and the Cayman Islands. Corvus Pharma is headquartered in Burlingame, California, US.

For a complete picture of Ciforadenant’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.